| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/13/2005 | US20050009831 Chemical compounds |
| 01/13/2005 | US20050009826 5,6,13-trizaza- or 6,13-diazachryseno[2,3-d]-[1,3]dioxole derivatives; enzyme inhibitors; anticarcinogenic, antiproliferative agents; bactericides, fungicides |
| 01/13/2005 | US20050009825 Cytotoxic agents |
| 01/13/2005 | US20050009824 Solubilized topoisomerase poisons |
| 01/13/2005 | US20050009822 7-(1-Acetylpentyl)-5-methyl-2-(4-methylbenzyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one; learning enhancement, concentration power, learning power, memory power; enzyme inhibitors of phosphodiesterase isoenzyme |
| 01/13/2005 | US20050009821 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 01/13/2005 | US20050009820 Thiochromenones used to combat painful conditions and neurodegenerative diseases |
| 01/13/2005 | US20050009818 Therapeutic heterocyclic compounds |
| 01/13/2005 | US20050009816 Potassium channel modulators |
| 01/13/2005 | US20050009815 4-Aminoquinoline compounds |
| 01/13/2005 | US20050009814 Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist |
| 01/13/2005 | US20050009813 Use of desoxypeganine for treating clinical depression |
| 01/13/2005 | US20050009812 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists |
| 01/13/2005 | US20050009811 Saquinavir mesylate oral dosage form |
| 01/13/2005 | US20050009810 synergistic combination of quinolinic antimalarial such as Chloroquine, Hydroxycloroquine, Mefloquine, or Quinine and HIV protease inhibitor such as indinavir, ritonavir, saquinavir, nelfinavir, lopinavir, amprenavir, fosamprenavir, tipranavir, atazanavir, or TMC-114 |
| 01/13/2005 | US20050009809 Acridine derivatives and their use as medicaments |
| 01/13/2005 | US20050009808 Azabicyclo compound matrix metalloprotease inibitor and skin preparation |
| 01/13/2005 | US20050009807 Preventing the deposits of amyloid protein, treating neurodegenerative disease, Alzheimer's disease and Down's Syndrome; {[carbamoyl]cycloalkyl}-N-(2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))- or (2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))-carboxamide |
| 01/13/2005 | US20050009806 Comprises angiotensin converting enzyme (ACE) inhibitors such as quinapril; improved shelf-life/storage stability |
| 01/13/2005 | US20050009805 Quaternary ammonium 1,4-benzothiazepinedione derivatives useful for treatment and prevention of hyperlipidemia, cholestasis-accompanying hepatopathy, particularly primary biliary cirrhosis and primary sclerosing cholangitis, and obesity and fatty liver. |
| 01/13/2005 | US20050009804 N-heterocyclyl- or cycloalkyl-N-(2-carboxy-5-aryl-3-thiophenyl)cycloalkanecarboxamides, e.g., 5-(3-fluorophenyl)-3-[isopropyl-(4-methylcyclohexanecarbonyl)amino]-thiophene-2-carboxylic acid; especially for prevention and treatment of HVC |
| 01/13/2005 | US20050009802 Tertiary amino-substituted, e.g, 1(4),8(11),15(18),22(25)-tetrakis[(3-(dimethylamino)phenoxy)phthalocyaninato] zinc; and their use as photodynamic therapeutic and photodiagnostic agents. |
| 01/13/2005 | US20050009800 Solid, free-flowing dry extract of a natural mixture of conjugated equine estrogens that has been applied by spraying an aqueous solution of the mixture onto a powdered or granular microcrystalline cellulose support that may contain lactose |
| 01/13/2005 | US20050009798 Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists |
| 01/13/2005 | US20050009796 Use of pregnane-diones or diols as neuropathic analgesic agents |
| 01/13/2005 | US20050009795 Mixtures or organic compounds for the treatment of airway diseases |
| 01/13/2005 | US20050009793 Treatment of liver disease with active vitamin D compounds |
| 01/13/2005 | US20050009792 (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses |
| 01/13/2005 | US20050009791 Especially lysine, arginine, histidine, omithine and diaminobutyric acid; improved solubility for parenteral administration |
| 01/13/2005 | US20050009790 Ear and wound treatment |
| 01/13/2005 | US20050009789 Administering a nitroxyl-donating diazeniumdiolate other than Angeli's salt or sulfi/NO for selectively inhibiting COX-2 inflammation without inhibiting the activity of COX-1 in non-inflamed cells ; screening candidate compounds for COX-2 inhibition |
| 01/13/2005 | US20050009788 The analog includes a conjugated polyene with 7 to 14 double bonds and a 3,3-dimethylcyclohexenylene or 3,3-dimethylcyclohexen-6-onylene ring; especially for treating cardiac arrhythmia and cancerous and pre-cancerous cells |
| 01/13/2005 | US20050009787 Complex of phosphate and ubiquinone, ascorbic acid, retinol, tocotriennol in mixture with carrier |
| 01/13/2005 | US20050009786 Immunosuppressant compounds and compositions |
| 01/13/2005 | US20050009785 Heterocyclic compounds |
| 01/13/2005 | US20050009784 2-(p-oxyphenyl)-6-oxyquinolines, e.g., 2-(3-Fluoro-4-hydroxyphenyl)-4-phenylquinolin-6-ol |
| 01/13/2005 | US20050009783 Adjust solubility; dissolving taxol and cyclodextrin compound in ethanol; stirring; heating |
| 01/13/2005 | US20050009782 Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof |
| 01/13/2005 | US20050009780 Use of oversulfated polysaccharides as inhibitors of hiv |
| 01/13/2005 | US20050009779 Preparation for improving the action of receptors |
| 01/13/2005 | US20050009778 Method for treating retinal degeneration with purinergic receptor agonists |
| 01/13/2005 | US20050009776 Using N-cyclopentyl-, 5-(N'-ethyl-)carboxamidoadenosine |
| 01/13/2005 | US20050009775 Hepatitis c virus; viricides |
| 01/13/2005 | US20050009774 Immunomodulatory oligonucleotides |
| 01/13/2005 | US20050009773 Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents |
| 01/13/2005 | US20050009770 Use of excipients to increase DNA uptake by swine muscle cells |
| 01/13/2005 | US20050009768 Using ribofuranosyl-1,2,4-triazole; in mixture with viricide |
| 01/13/2005 | US20050009767 Use of ribofuranose derivatives against inflammatory bowel diseases |
| 01/13/2005 | US20050009766 Use of ribofuranose derivatives against inflammatory bowel diseases |
| 01/13/2005 | US20050009762 Stability, palatable solution; parasiticides |
| 01/13/2005 | US20050009760 Methods and compositions for treatment of ataxia-telangeictasia |
| 01/13/2005 | US20050009759 Anticancer agents |
| 01/13/2005 | US20050009758 Therapy for ischemic-repefusion injuries; liver disorders; antiarrhythmia agents; anticancer agents; astaxanthin |
| 01/13/2005 | US20050009757 Sphingosine derivative; immunomoderator; microbiocides; therapy for infections; tuberculosis |
| 01/13/2005 | US20050009756 Polymorph of a pharmaceutical |
| 01/13/2005 | US20050009754 Genetically engineered growth hormone; administering with antidepressant |
| 01/13/2005 | US20050009748 Compositions for delivering peptide YY and PYY agonists |
| 01/13/2005 | US20050009744 Treatment of congestive heart failure |
| 01/13/2005 | US20050009742 Compounds and methods for increasing neurogenesis |
| 01/13/2005 | US20050009736 Administering by hemodilution an aqueous cell-free polyalkylene oxide surface modified hemoglobin without intramolecular crosslinking; oxygen affinity greater than whole blood; blood disorders |
| 01/13/2005 | US20050009733 Synergistic mixture; stroke therapy |
| 01/13/2005 | US20050009732 Antigrowth agents; anticancer agents; sphingosine kinase |
| 01/13/2005 | US20050009731 Propofol formulations with non-reactive container closures |
| 01/13/2005 | US20050009730 Sleep disorders; side effect reduction |
| 01/13/2005 | US20050009144 Transgenic cell comprising nucleotide sequences coding endostatins for use as tool in identifying modulators for treatment and prevention of cell proliferative and angiogenesis-related disorders |
| 01/13/2005 | US20050009140 Elongase genes and uses thereof |
| 01/13/2005 | US20050009105 Compositions and methods for the diagnosis and treatment of tumor |
| 01/13/2005 | US20050009085 44 Human secreted proteins |
| 01/13/2005 | US20050009043 Prodrugs of phosphonate nucleotide analogues |
| 01/13/2005 | US20050009030 Histone deacetylase: novel molecular target of neurotoxicity |
| 01/13/2005 | US20050009021 Isolated nucleic acid comprising polynucleotide of given sequence; diagnostic kits; use in treatment of cancer |
| 01/13/2005 | US20050008726 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
| 01/13/2005 | US20050008725 Synergistic mixture; adjust fat metabolism |
| 01/13/2005 | US20050008724 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
| 01/13/2005 | US20050008723 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
| 01/13/2005 | US20050008722 Compositions incorporating(-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
| 01/13/2005 | US20050008718 Identification of compositions, compositions, and methods of treatment of obesity and overweight conditions |
| 01/13/2005 | US20050008717 Anti-neoplastic compositions comprising extracts of black cohosh |
| 01/13/2005 | US20050008716 Synergistic composition for the treatment of diabetes mellitus |
| 01/13/2005 | US20050008713 Compositions of plant carbohydrates as dietary supplements |
| 01/13/2005 | US20050008712 Obesity therapy |
| 01/13/2005 | US20050008711 Using plant extracts |
| 01/13/2005 | US20050008707 Nanoparticulate megestrol formulations |
| 01/13/2005 | US20050008703 Medical formulation containing a muscarinic agonist |
| 01/13/2005 | US20050008701 Formulation and process for drug loaded cores |
| 01/13/2005 | US20050008699 Effervescent glucosamine composition |
| 01/13/2005 | US20050008697 Oral solid solution formulation of a poorly water-soluble active substance |
| 01/13/2005 | US20050008695 Compositions and methods for delivering a biologically active agent |
| 01/13/2005 | US20050008694 Vaginally administratable progesterone-containing tablets and method for preparing same |
| 01/13/2005 | US20050008692 Compositions comprising pectin and ascorbic acid |
| 01/13/2005 | US20050008691 Bicalutamide compositions |
| 01/13/2005 | US20050008689 High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| 01/13/2005 | US20050008688 Oral administering; tablet with enteric coating; supplying drug to gastrointestinal systems |
| 01/13/2005 | US20050008687 Antioxidant; anticancer agents |
| 01/13/2005 | US20050008685 Mixture containing liposome electrolytes |
| 01/13/2005 | US20050008684 Method of treatment for acne, rosacea and ulcers with taurolidine and/or taurultam in a pharmaceutical composition |
| 01/13/2005 | US20050008679 synergistic efficacy; polar lipid supplement which contains antioxidants; soluble beta-glucan fiber; nutricine which enhances growth and/or strengthens the immune system; and a protein concentrate supplement such as whey protein concentrate |
| 01/13/2005 | US20050008678 Solid foods; creatine suspended in support matrix |
| 01/13/2005 | US20050008671 Methods and compositions for the inhibition of biofilms on medical devices |
| 01/13/2005 | US20050008665 Mixture of antioxidant and hexadecenedicarboxylic acid |